Allemani 2018: CONCORD-3, global surveillance of cancer survival 2000 to 2014
The largest comparison of cancer survival between countries, covering 37.5 million patients in 71 countries, found survival rising for most cancers but with very wide gaps between countries, especially for children's cancers and cancers that depend on early diagnosis and good treatment access.
Overview
CONCORD-3 analysed individual records for 37.5 million patients diagnosed with one of 18 cancers between 2000 and 2014, supplied by 322 population-based registries in 71 countries and territories, and estimated five-year net survival by country and period. Survival was rising for most cancers in most countries, including steep rises for liver and lung cancers in some countries, but international differences remained very wide. The paper documented, for example, breast cancer survival in the high 80s and 90s of percent in Australia and the United States against the mid-60s in India, and childhood brain tumour survival ranging from under 40% to over 80%.
- 37.5 million patient records for 18 cancers from 322 registries in 71 countries, diagnosed 2000 to 2014.
- Five-year net survival increased for most cancers in most countries over the period.
- Five-year breast cancer survival about 90% in the United States and Australia versus about 66% in India; childhood brain tumour survival ranged from under 40% to over 80% between countries.
- Survival for oesophageal, liver, lung and pancreatic cancers remained low almost everywhere.
CONCORD is the evidence base for national cancer plans and for the statement that where you live changes your chance of surviving cancer. Its country tables are the benchmark health systems use to judge early diagnosis and treatment access.
- Registry coverage and data quality vary widely; some countries contributed only regional registries.
- Net survival compares against general population mortality and is affected by screening-detected, slow-growing cancers.
Similar pages
not linked directly; found by shared links- Key paperChen 2016: Cancer statistics in China, 2015
Shares Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers, Mortality, Hepatocellular carcinoma, Colorectal cancer.
- Key paperTorre 2015: Global cancer statistics, 2012
Shares Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers, Mortality, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer.
- Key paperFitzmaurice 2017: the Global Burden of Disease estimate of cancer in 2015
Shares Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers, Mortality, Non-small-cell lung cancer.
- Key paperSung 2021: GLOBOCAN 2020, the year breast cancer overtook lung cancer as the most diagnosed cancer
Shares Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers, Mortality, Colorectal cancer, HR-positive / HER2-negative breast cancer.
- Key paperCalle 2003: overweight, obesity and death from cancer in 900,000 US adults
Shares Mortality, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- Key paperSiegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report
Shares Mortality, Pancreatic ductal adenocarcinoma, Colorectal cancer, HR-positive / HER2-negative breast cancer.
- Key paperBray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries
Shares Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers, Colorectal cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer.
- TreatmentJK08
Shares Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer, HR-positive / HER2-negative breast cancer.